The Division of Internal Oncology provides systemic cancer treatment. The Department of Lymphoma Treatment performs treatments of lymphoma, plasmocytoma, and cancers of unknown primary; and the Department for Solid Cancer Treatment carries out treatments of melanoma and other skin cancers, gastrointestinal cancer, sarcoma, lung cancer, breast cancer, gynaecological cancers, urological cancers, head and neck cancers, rare cancers, and cancers of unknown primary. The employees provide prevention, gene counselling, diagnostics and early cancer treatments, treatment of locoregionally advanced cancer and metastatic diseases, and symptomatic and palliative treatment. They monitor patients and treat surgical complications of systemic treatments. They introduce new methods of systemic treatment and participate in international clinical trials, which provides their patients with an early access to new systemic treatments.
In all filed of systemic treatment, they follow novelties and introduce them in both diagnostics and systemic treatments. According to these trends and many biomarkers, systemic treatments are becoming more adapted to individual patients and the characteristics of their tumours; treatments are being individualised. Treatments are becoming more and more outpatient, enabling patients to remain in their home environments longer and, thus, improving the quality of their lives.
Head of the Division of Medical Oncology
Assoc. prof. Janja Ocvirk, MD, PhD
T: +386 1 5879 280